BIOLINERX LTD-SPONS ADR (BLRX)
US09071M2052 - ADR
Thursday's session: top gainers and losers
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Thursday's session: gap up and gap down stocks
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Get insights into the top gainers and losers of Thursday's pre-market session.
Get insights into the top gainers and losers of Thursday's pre-market session.
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as...
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BLRX Stock Earnings: BioLine Rx Beats Revenue for Q2 2024
BLRX stock results show that BioLine Rx beat on revenue for the second quarter of 2024.
BLRX Stock Earnings: BioLine Rx Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the second quarter of 2024.T...
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Tuesday morning!
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real.
BLRX Stock Earnings: BioLine Rx Beats EPS for Q1 2024
BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the first quarter of 2024.
BLRX Stock Earnings: BioLine Rx Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the first quarter of 2024.Bi...
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Steady growth in APHEXDA® adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at...
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing...
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
BioLineRx Announces $6 Million Registered Direct Offering
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing...
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
BLRX stock results show that BioLine Rx beat analyst estimates for earnings per share the fourth quarter of 2023.
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ:BLRX) just reported results for the fourth quarter of 2023.B...
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on...
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
When you want to light your afterburners, these ideas will do the trick.
BioLineRx files for a $250M mixed securities shelf (NASDAQ:BLRX)
BioLineRx (BLRX) has filed a prospectus for a mixed shelf offering to raise up to $250M, indicating potential growth in their financial capital.
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
biolinerx GAAP EPS of -$0.01 (NASDAQ:BLRX)
BiolineRx, a biopharmaceutical company, reports Q3 2023 financial results, with a GAAP EPS of -$0.01.
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
- Received FDA Approval of APHEXDA® (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent...
3 Tech Stocks That Wall Street Loves More Than Nvidia
Purchase these top tech stocks now to achieve maximum profits and allow your portfolio to skyrocket given the volatile market.
3 Top Penny Stocks to Make You a Millionaire in 5 Years
Penny stocks can make you a millionaire with patience and luck especially when you follow secular trends overall.
BioLineRx announces closing of exclusive license agreement with GloriaBio (NASDAQ:BLRX)
BioLineRx announced a license agreement with GloriaBio for the development of motixafortide in Asia, including potential milestones and equity investment.
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
- License agreement includes $15 million upfront, up to $50 million in potential development and regulatory milestones; up to ~$200 million in potential...